Due to the insulin resistance in nonalcoholic fatty liver disease, insulin sensitizers can be used to treat the disease by promoting the binding of insulin to its receptor and accelerating the uptake of glucose into peripheral tissues [15]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.